Elicera Therapeutics (Q1 Review): Funding secured, plenty of triggers ahead - Redeye
Bildkälla: Stockfoto

Elicera Therapeutics (Q1 Review): Funding secured, plenty of triggers ahead - Redeye

Redeye returns with a research update after Elicera's Q1 update and announced rights issue. We revisit ELC-401 and discuss our expectations ahead.

Redeye returns with a research update after Elicera's Q1 update and announced rights issue. We revisit ELC-401 and discuss our expectations ahead.
Börsvärldens nyhetsbrev